GANX News and Press, Gain Therapeutics Inc. From 09/08/21

Gainers: Kadmon KDMN +73%, ICU Medical ICUI +32%, Candel Therapeutics CADL +17%, Gain Therapeutics GANX +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -19%, Alector A...

Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...

GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synuclein-p129 levels --- ...

David Einhorn's 13F stock portfolio value increased from $1.44B to $1.59B this quarter. Greenlight increased Teck Resources, GoPro, and The ODP Corp while reducing APi Group, CNX Resources, and Katapult Holdings during the quarter. They also dropped ADT Inc. and Alight Inc. The la...

BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lys...

Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer’s Dise...

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases an...

BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publi...

David Einhorn's 13F stock portfolio value decreased from $1.66B to $1.44B this quarter. Greenlight increased Danimer Scientific and Concentrix while reducing AerCap Holdings, fuboTV, and Resideo Technologies during the quarter. The largest three positions are at ~45% of the portfo...